Name: Xu Jie
Highest Degree: Ph.D.
Position Title: Professor, Director
Email: jie_xu@fudan.edu.cn
Address: Room 107, Scientific Research Building, Fudan University
Dr. Xu Jie is a Professor and Director of the Shanghai Key Laboratory for Discovery of Novel Anti-tumor Drug Targets and Antibody Therapeutics (Preparatory) at the School of Pharmacy, Fudan University. He obtained his Ph.D. in Life Sciences Engineering from Université libre de Bruxelles. With a background in clinical medicine and extensive postdoctoral experience, Dr. Xu has dedicated his career to discovering novel tumor therapeutic targets and developing antibody-based drugs. His work has led to the identification of original targets such as CD3L1 and the advancement of candidate antibodies into clinical trials. Dr. Xu has published extensively in high-impact journals including Cell and Nature Biomedical Engineering, and has transferred patents with a total value exceeding RMB 228 million.
Tumor immunotherapy,
antibody drug development,
immune checkpoint regulation,
targeted protein degradation,
translational medicine
Education
● Ph.D. in Life Sciences Engineering, Université libre de Bruxelles, Belgium (2006–2010)
● M.Med. & B.Med. in Clinical Medicine (7-year program), Harbin Medical University, China (1998–2005)
Professional Experiences
● Professor & Director, Shanghai Key Laboratory for Discovery of Novel Anti-tumor Drug Targets and Antibody Therapeutics (Preparatory), School of Pharmacy, Fudan University (2025–present)
● Professor, Institute of Biomedical Sciences, Fudan University (2019–2025)
● Associate Professor/Professor, Shanghai Jiao Tong University School of Medicine (2012–2019)
● Postdoctoral Researcher, VIB (Flanders Institute for Biotechnology), Belgium (2010–2011)
● Resident/Attending Physician, General Surgery Department, Tenth People’s Hospital of Tongji University (2005–2006)
Grants & Projects
● Preclinical study of original anti-tumor target CTA6 antibody-drug conjugate (82441037), National Natural Science Foundation of China (NSFC), Special Program, 2025–2027, RMB 6.2 million
● Discovery of lead compounds for tumor immunotherapy based on immune checkpoint protein degradation (82030104), NSFC Key Program, 2021–2025, RMB 2.97 million
● Screening and clinical translation of key signaling pathways and specific biomarkers in bone and soft tissue tumors (2024ZD0525800), National Major Science and Technology Project, 2025–2029, RMB 2.37 million
● Mechanism of ITPRIPL1 in regulating T cells in the tumor microenvironment (82473939), NSFC General Program, 2025–2028, RMB 480,000
Awards & Honors
● National Science and Technology Progress Award (Second Class, 4th contributor), 2018
● Shanghai Health System Silver Snake Award (Second Class), 2015
● National Leading Talent in Technological Innovation, 2022
● National Young Top-Notch Talent Support Program, 2016
● NSFC Excellent Young Scientist Fund, 2013
● Tang Scholar, Oriental Scholar, Shanghai Dawn Scholar, Shanghai Rising-Star Scholar, Shanghai Pujiang Talent
Memberships
● China Anti-cancer Association, member
Invited Presentations
● Lecture in Japan Cancer Association symposium 25th
Selected Publications (Latest 5 Years, <20)
● Deng S, Zhang Y, Wang H, et al. ITPRIPL1 binds CD3ε to impede T-cell activation and enable tumor immune evasion. Cell. 2024.
● Chi H, Deng S, Xu K, et al. SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint. Cancer Res. 2025.
● Wang Y, Sun Y, Deng S, et al. Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs. Cell Rep Med. 2024.
● Wang H, Yao H, Li C, et al. HIP1R targets PD-L1 to lysosomal degradation. Nat Chem Biol. 2019.
● Yao H, Lan J, Li C, et al. Inhibiting PD-L1 palmitoylation enhances T-cell responses. Nat Biomed Eng. 2019.
● Li C, Chi H, Deng S, et al. THADA drives Golgi residency and upregulation of PD-L1. J Immunother Cancer. 2021.
● Liang L, Wang H, Shi H, et al. A Designed Peptide Targets Two Types of p53 Modifications. Cell Chem Biol. 2018.
● Li C, Yao H, Wang H, et al. Amlodipine induces PD-L1 degradation and antitumor immunity. Oncogene. 2020.
● Xu J (Ed.). Regulation of Cancer Immune Checkpoints. Springer, 2020.
Patents
● Multiple patents related to antibody drug development with total transfer value exceeding RMB 228 million.
● Original antibody drug candidates against novel targets have entered Phase Ib/IIa clinical trials in the U.S. and China.
